Search
Displaying 951–960 of 1083 results
-
SparingVision Formed to Advance Sight-Saving Protein for RP
Research NewsSparingVision received a €300,000 award known as the Honor Prize from the French Ministry of Research. The award is given to new, innovative companies in France competing in a national contest.
-
Researchers Find Mutation as Frequent Cause of RP in American Hispanics
Research NewsThe discovery can help genetic experts diagnose more patients with adRP, and it gives researchers a target for developing potential therapies.
-
Valproic Acid's Effect Too Small in One-Year Clinical Trial
Research NewsWhile a therapy for adRP will not emerge from the clinical trial, study investigators advanced development of a new outcome measure known as EZ Area to quickly and accurately evaluate potential therapies for RP in human studies.
-
Forty-Four High-Impact Retinal-Research Efforts Highlighted at FFB-Casey Innovation Summit
Research NewsIn its fourth year, the meeting is becoming the world’s most comprehensive overview of the promising research underway for emerging IRD treatments.
-
Clinical Trial Authorized in the U.S. for Emerging LCA 10 Therapy
Research NewsProQR, a biotechnology company in the Netherlands, has received authorization from the U.S. Food and Drug Administration to start a Phase I/II clinical trial for its therapy known as QR-110
-
FFB Funding Helps Retinal Genetics Lab Secure $2 Million Investment
Research NewsHow the Foundation Fighting Blindness (FFB) provided timely funding of $155,000 to help a lab at the University of California, San Diego (UCSD), leverage a $2 million retinal-gene discovery project.
-
jCyte Stem-Cell Therapy Moves into Phase IIb Clinical Trial for RP
Research NewsBased on lab studies, researchers believe the treatment can preserve and potentially rescue the patient’s existing photoreceptors, thereby saving and possibly restoring vision.
-
FFB-CRI Launching Natural History Study for People with USH2A Mutations
Research NewsThe study — known as RUSH2A (“R” stands for “rate of progression”) — is beginning in spring 2017 and will take place at about 20 clinical sites around the world. RUSH2A investigators will use a variety of technologies to monitor changes in vision and retinal structure to document and analyze disease progression.
-
Dr. Eliot Berson, Pioneer in Vitamin A Therapy for Retinitis Pigmentosa, Passes Away
Research NewsDr. Berson dedicated himself to clinical care and vision-saving research for people with inherited retinal diseases for five decades.
-
First Patient Treated in XLRP Gene Therapy Clinical Trial
Research NewsThe Nightstar gene therapy involves injection of healthy copies of RPGR underneath the retina.
